Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Evofem Biosciences Inc., (NASDAQ: EVFM) today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.
Evofem's CEO, Saundra Pelletier, will provide updates on the commercialization of Phexxi® (lactic acid, citric acid and potassium bitartrate), the first and only FDA-approved, hormone free contraceptive vaginal gel, and the pivotal Phase 3 EVOGUARD trial, which is evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and currently enrolling subjects at study centers across the U.S.
The presentation will be available for on-demand listening beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the Investors section of the Evofem Biosciences website at www.evofem.com, under the Events and Presentations tab.
About Evofem Biosciences
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-the-hc-wainwright-bioconnect-2021-virtual-conference-301196515.html
SOURCE Evofem Biosciences, Inc.
Company Codes: NASDAQ-NMS:EVFM